标题
Pancreatic cancer, treatment options, and GI-4000
作者
关键词
-
出版物
Human Vaccines & Immunotherapeutics
Volume 11, Issue 4, Pages 931-937
出版商
Informa UK Limited
发表日期
2015-05-28
DOI
10.1080/21645515.2015.1011017
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Gemcitabine Adjuvant Therapy for Resected Pancreatic Cancer
- (2015) Zhong Yu et al. AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS
- Oncogenic KRAS signalling in pancreatic cancer
- (2014) S Eser et al. BRITISH JOURNAL OF CANCER
- Phase II Study of the GI-4000 KRAS Vaccine After Curative Therapy in Patients With Stage I-III Lung Adenocarcinoma Harboring a KRAS G12C, G12D, or G12V Mutation
- (2014) Jamie E. Chaft et al. Clinical Lung Cancer
- Albumin-Bound Paclitaxel plus Gemcitabine in Pancreatic Cancer
- (2014) NEW ENGLAND JOURNAL OF MEDICINE
- KRAS: feeding pancreatic cancer proliferation
- (2014) Kirsten L. Bryant et al. TRENDS IN BIOCHEMICAL SCIENCES
- Kras as a key oncogene and therapeutic target in pancreatic cancer
- (2014) Meredith A. Collins et al. Frontiers in Physiology
- Understanding the Biology of Antigen Cross-Presentation for the Design of Vaccines Against Cancer
- (2014) Cynthia M. Fehres et al. Frontiers in Immunology
- Exploiting inflammation for therapeutic gain in pancreatic cancer
- (2013) C W Steele et al. BRITISH JOURNAL OF CANCER
- Phase I trial of a recombinant yeast-CEA vaccine (GI-6207) in adults with metastatic CEA-expressing carcinoma
- (2013) Marijo Bilusic et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Inflammatory networks and immune surveillance of pancreatic carcinoma
- (2013) Robert H Vonderheide et al. CURRENT OPINION IN IMMUNOLOGY
- GI-4000 inKRASmutant cancers
- (2013) Safi Shahda et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Roles for KRAS in Pancreatic Tumor Development and Progression
- (2013) Marina Pasca di Magliano et al. GASTROENTEROLOGY
- T and NK cells: two sides of tumor immunoevasion
- (2013) Doriana Fruci et al. Journal of Translational Medicine
- Adjuvant treatments for resected pancreatic adenocarcinoma: a systematic review and network meta-analysis
- (2013) Wei-Chih Liao et al. LANCET ONCOLOGY
- Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
- (2013) Daniel D. Von Hoff et al. NEW ENGLAND JOURNAL OF MEDICINE
- Mutant KRAS is a druggable target for pancreatic cancer
- (2013) E. Zorde Khvalevsky et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Internalization and endosomal degradation of receptor-bound antigens regulate the efficiency of cross presentation by human dendritic cells
- (2012) B. Chatterjee et al. BLOOD
- Vaccines for Pancreatic Cancer
- (2012) Kevin C. Soares et al. CANCER JOURNAL
- Oncogenic Kras Maintains Pancreatic Tumors through Regulation of Anabolic Glucose Metabolism
- (2012) Haoqiang Ying et al. CELL
- What Is Recent in Pancreatic Cancer Immunotherapy?
- (2012) Elena Niccolai et al. Biomed Research International
- Hallmarks of Cancer: The Next Generation
- (2011) Douglas Hanahan et al. CELL
- Current Immunotherapeutic Approaches in Pancreatic Cancer
- (2011) Shigeo Koido et al. Clinical & Developmental Immunology
- FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer
- (2011) Thierry Conroy et al. NEW ENGLAND JOURNAL OF MEDICINE
- TGF-β and immune cells: an important regulatory axis in the tumor microenvironment and progression
- (2010) Li Yang et al. TRENDS IN IMMUNOLOGY
- Adjuvant Interferon alfa for melanoma: new evidence-based treatment recommendations?
- (2009) Axel Hauschild Current Oncology
- Myeloid-Derived Suppressor Cells: Linking Inflammation and Cancer
- (2009) S. Ostrand-Rosenberg et al. JOURNAL OF IMMUNOLOGY
- Dendritic cell subsets in primary and secondary T cell responses at body surfaces
- (2009) William R Heath et al. NATURE IMMUNOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started